Cardiovascular Research

The effects of amlodipine compared to losartan in patients with mild to moderately severe hypertension.

Authors: Robert A Phillips|||Robert A Kloner|||Richard H Grimm|||Myron Weinberger

Affiliations: + Expand

Abstract

The calcium channel blocker amlodipine and angiotensin II receptor blocker losartan, with or without hydrochlorothiazide (HCTZ), were compared for the treatment of mild to moderate hypertension in a multicenter, double-blind, parallel-group clinical trial. Following a 2-week placebo run-in, 440 adults (45-80 years old) were randomized to receive either amlodipine 5 mg once daily or losartan 50 mg once daily. Patients who failed to meet the sitting diastolic blood pressure (BP) reduction goal of

---

Chemical List

Antihypertensive Agents|||Calcium Channel Blockers|||Hydrochlorothiazide|||Amlodipine|||Losartan

---

Reference List

Whelton PK. Epidemiology of Hypertension. Lancet. 1994;344:101–106.||| McMahon S, Peto R, Cutler J, Blood pressure, stroke, and coronary heart disease, part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–774. ||| Collins R, Petro R, MacMahon S, Blood pressure, stroke, and coronary heart disease, part II: short‐term reductions in blood pressure: overview of randomized clinical trials in their epidemiological context. Lancet. 1990;335:827–838. ||| Whelton PK, Perneger TV, Klag MJ, Epidemiology of blood pressure‐related renal disease. J Hypertens. 1992;10(suppl 7):S77–S84. |||Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic and cardiovascular risks: U. S. population data. Arch Intern Med. 1993;153:598–615.||| Messeri P, Workman S, Saunders C, The application of meta‐analysis in assessing racial differences in the effects of antihypertensive medication. J. Nat Med Assn. 1997;89:477–485. |||Messerli FH, Grossman E, Goldbourt U. Are beta‐blockers efficacious as first‐line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23): 1903–1907.||| Nelsen LM, Himmelberger DU, Morrison A, Quality‐of‐life questionnaire for patients taking antihypertensive medication. Clin Ther. 1999;21(10):1771–1787. |||Moser M. The cost of treating hypertension: can we keep it under control without compromising level of care? Am J. Hypertens. 1998;11(8 pt 2):S120–S127.||| Mancia G, Dell‐Oro R, Turri C, Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol. 1999;84(10A):28S–34S. |||Wilson TW, Lacourciere Yves, Barnes CC. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. CMAJ. 1998;159(5):469–476.|||The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157(21): 2413–2446.||| Hansson L, Zansson L, Zanchetti A, , for the HOT Study Group. Effects of intensive blood‐pressure lowering and low‐dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:1755–1762. ||| Staessen J, Thijs L, Gasowski J, , for the Systolic Hypertension in Europe (Syst‐Eur) Trial Investigators. Treatment of isolated systolic hypertension in the elderly: further evidence from the Systolic Hypertension in Europe (Syst‐Eur) Trial. Am J Cardiol. 1998;82:20R–22R. ||| Hansson L, Lindholm LH, Ekbom T, , For the STOP‐Hypertension‐2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension‐2 study. Lancet. 1999;354: 1751–1756. ||| Brown MJ, Palmer CR, Castaigne A, Morbidity and mortality in patients randomized to double‐blind treatment with a long‐acting calcium‐channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366–372. ||| Hansson L, Hedner T, Lund‐Johansen P, Randomised trial of effects of calcium antagonists compared with diuretics and β‐blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359–365. ||| Parati G, Ravogli A, Frattola A, Blood pressure variability: clinical implications and effects of antihypertensive treatment. J Hypertens Suppl. 1994;12(5):S35–S40. |||Millar‐Craig MW, Vishop CN, Rafferty EB. Circadian variation of blood pressure. Lancet. 1978;I:795–797.|||Ackermann RJ, Meyer von Bremen GB. Reducing polypharmacy in the nursing home: an activist approach. Am Board Fam Pract. 1995;8(3):195–205.||| Lewis EJ, Hunsicker LG, Clarke WR, Renoprotective effect of the angiotensin‐receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860. ||| Agadoa LY, Appel L, Bakris GL, , for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728. ||| Brenner BM, Cooper ME, de Zeeuw D, Effects of losartan on renal cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869. ||| Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee . . Rockville , MD : National Press Office; January 7, 2002. ||| Dahlof B, Devereux RB, Kjeldsen SE, , for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995–1003. |||The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group . Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid‐Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283: 1967–1975.